The upcoming report from BioMarin Pharmaceutical (BMRN) is expected to reveal quarterly earnings of $0.73 per share, indicating an increase of 49% compared to the year-ago period. Analysts forecast revenues of $711.93 million, representing an increase of 10.2% year over year.
Over the last 30 days, there has been a downward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific BioMarin metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts forecast 'Revenues- Net product revenues' to reach $703.12 million. The estimate indicates a year-over-year change of +11.1%.
Analysts expect 'Revenues- Royalty and other revenues' to come in at $10.07 million. The estimate indicates a year-over-year change of -22.9%.
Analysts predict that the 'Revenues- Net Product Revenues- NAGLAZYME' will reach $122.60 million. The estimate suggests a change of +24.7% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Net Product Revenues- VIMIZIM' of $181.70 million. The estimate indicates a year-over-year change of +3.5%.
The average prediction of analysts places 'Revenues- Net Product Revenues- PALYNZIQ' at $94.03 million. The estimate indicates a change of +7.1% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenues- Net Product Revenues- VOXZOGO' should arrive at $201.43 million. The estimate indicates a year-over-year change of +38.3%.
The combined assessment of analysts suggests that 'Revenues- Net Product Revenues- KUVAN' will likely reach $23.55 million. The estimate points to a change of -35.8% from the year-ago quarter.
The consensus estimate for 'Revenues- Net Product Revenues- ALDURAZYME' stands at $28.13 million. The estimate points to a change of -34.1% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Net Product Revenues- BRINEURA' should come in at $43.36 million. The estimate indicates a year-over-year change of -0.6%.
View all Key Company Metrics for BioMarin here>>>
BioMarin shares have witnessed a change of +7% in the past month, in contrast to the Zacks S&P 500 composite's +3.9% move. With a Zacks Rank #2 (Buy), BMRN is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpBioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
